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Abstract
OBJECTIVE—Reductions in heart attack and stroke hospitalizations are well documented in the 
U.S. population with diabetes. We extended trend analyses to other cardiovascular disease (CVD) 
conditions, including stroke by type, and used four additional years of data.
RESEARCH DESIGN AND METHODS—Using 1998–2014 National (Nationwide) Inpatient 
Sample data, we estimated the number of discharges having acute coronary syndrome (ACS) 
(ICD-9 codes 410–411), cardiac dysrhythmia (427), heart failure (428), hemorrhagic stroke (430–
432), or ischemic stroke (433.x1, 434, and 436) as first-listed diagnosis and diabetes (250) as 
secondary diagnosis. Hospitalization rates for adults aged ≥35 years were calculated using 
estimates from the population with and the population without diabetes from the National Health 
Interview Survey and age-adjusted to the 2000 U.S. standard population. Joinpoint regression was 
used to analyze trends and calculate an average annual percentage change (AAPC) with 95% 
confidence limits (CLs).
RESULTS—From 1998 to 2014, in the population with diabetes, age-adjusted hospitalization 
rates declined significantly for ACS (AAPC −4.6% per year [95% CL −5.3, −3.8]), cardiac 
dysrhythmia (−0.7% [−1.1, −0.2]), heart failure (−3.6% [ −4.6, −2.7]), hemorrhagic stroke (−1.1% 
[−1.4, −0.7]), and ischemic stroke (−2.9% [−3.9, −1.8]). In the population without diabetes, rates 
also declined significantly for these conditions, with the exception of dysrhythmia. By 2014, rates 
in the population with diabetes population remained two to four times as high as those for the 
population without diabetes, with the largest difference in heart failure rates.
CONCLUSIONS—CVD hospitalization rates declined significantly in both the population with 
diabetes and the population without diabetes. This may be due to several factors, including new or 
more aggressive treatments and reductions in CVD risk factors and CVD incidence.
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Diabetes is a major cause of cardiovascular disease (CVD) and a leading cause of blindness, 
kidney failure, and lower-limb amputations among adults (1–5). For every four adults with 
diagnosed diabetes, three have high blood pressure, a risk factor for CVD (1). Compared 
with people without diabetes, the risk for stroke is approximately two to four times as high 
and CVD death rates are about two times as high among people with diabetes (6,7).
Recent national data have documented reductions in mortality due to all-cause and CVD in 
the population with diabetes as well as improvements in several diabetes-related 
complications such as lower-limb amputations, kidney failure, acute myocardial infarction 
(AMI), and stroke (7,8). Of these complications, the largest absolute declines in rates 
between 1990 and 2010 were observed for AMI and stroke hospitalizations (8). These 
reports documenting improvements in diabetes-related morbidity and mortality are 
encouraging and may be due in part to improvements in the health of people with diabetes, 
including earlier diagnosis (9), better control of risk factors for complications (e.g., 
hyperglycemia and high blood pressure) (10,11), and improvements in quality of care and 
medical treatments (12). However, a recent study of CVD hospitalizations in the population 
with diabetes was limited in the number of CVD conditions examined (i.e., AMI and stroke) 
and did not examine stroke by type (8). We extended the analysis to other CVD conditions, 
including stroke by type, and used four additional years of data. We assessed whether 
disparities in rates between the population with diabetes and the population without diabetes 
were reduced or continued to persist, and in the population with diabetes, we looked at 
trends in hospitalizations by age, sex, and race/ethnicity.
RESEARCH DESIGN AND METHODS
We estimated the number of hospital discharges due to various CVD conditions among 
persons with and without diagnosed diabetes using 1998–2014 data from the National 
(Nationwide) Inpatient Sample (NIS) of the Agency for Healthcare Research and Quality 
(13,14). NIS contains information from >7 million hospital stays each year from 44 states 
participating in the Agency for Healthcare Research and Quality’s Healthcare Cost and 
Utilization Project, estimating >35 million hospitalizations nationally and representing 
>95% of the U.S. population. The NIS was redesigned in 2012; a more detailed description 
of the NIS is available (13,14). Data collected include information on patients’ age, race, 
sex, length of stay, and 15 diagnoses (one primary and 14 secondary diagnoses). 
Hospitalizations for all individuals were included regardless of discharge disposition (i.e., 
whether the patient was discharged alive or died during the hospitalization). We identified 
discharges for which the first-listed diagnosis was acute coronary syndrome (ACS) (ICD-9 
codes 410–411), cardiac dysrhythmia (427), heart failure (428), or stroke (430–432, 433.x1, 
434, and 436). Codes for ACS include AMI, angina, and coronary atherosclerosis; codes for 
cardiac dysrhythmia include cardiac arrest. Stroke discharges were subdivided into 
hemorrhagic stroke (430–432) and ischemic stroke (433.x1, 434, and 436); transient cerebral 
ischemia (435) was not included. The discharges were considered to be diabetes-related if 
diabetes (250) was listed as a secondary diagnosis.
Estimates of the population with and the population without diagnosed diabetes were 
obtained from the 1998–2014 National Health Interview Survey (NHIS). Conducted 
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continuously since 1957, the NHIS is a health survey of the civilian, non-institutionalized, 
household population of the U.S. The multistage probability design of the survey has 
previously been described (15).The survey provides information on the health of the U.S. 
population, including information on the prevalence and incidence of disease, the extent of 
disability, and the use of health care services. For gathering information about diagnosed 
diabetes, respondents were asked whether they had ever been told by a doctor or health 
professional that they had diabetes or sugar diabetes (other than during pregnancy for 
women).
We calculated CVD-specific hospitalization rates per 1,000 population (with diabetes or 
without diabetes) by dividing the estimated number of discharges with and discharges 
without diagnosed diabetes from NIS by the estimated populations with and population 
without diagnosed diabetes from NHIS. We compared overall trends in hospitalization rates 
for ACS, heart failure, cardiac dysrhythmia, and hemorrhagic and ischemic stroke by 
diabetes status. Among those with diagnosed diabetes, we also examined trends by age (35–
54, 55–74, and ≥75 years), sex, and race/ethnicity (non-Hispanic whites, non-Hispanic 
blacks, and Hispanics). We restricted our analysis to discharge records of patients aged ≥35 
years because of the smaller sample size of these CVD conditions among people, <35 years 
old. People of “other races” and people with missing race/ethnicity data were excluded only 
from the race/ethnicity-specific analysis in the population with diabetes. In NIS, during the 
study period, missing race/ethnicity data in the population with diabetes ranged from 1 to 
4%.
We used SUDAAN 11 (SAS callable) software (Research Triangle Institute, Research 
Triangle Park, NC) to obtain point estimates and SEs based on the Taylor series linearization 
method and to account for the complex sampling designs of the two surveys. We adjusted 
rates to the 2000 U.S. standard population using age-groups (35–54, 55–74, and ≥75 years), 
used the χ2 test to determine whether differences in hospitalization rates between various 
subgroups were significant, and calculated annual CVD-specific hospitalization rate ratios 
by dividing the diabetes-related rates by the non–diabetes-related rates.
To analyze trends in hospitalization rates, we used Joinpoint regression software (version 
4.3.1.0; Statistical Methodology and Applications Branch and Data Modeling Branch, 
Surveillance Research Program, National Cancer Institute). Joinpoint regression uses 
permutation tests to identify points where linear trends change significantly in either 
direction or magnitude. Each trend segment is described by an annual percentage change 
(APC) and the trend for the entire study period is described by the average annual 
percentage change (AAPC), which is a summary measure of trend accounting for transitions 
within each trend segment. Both trend measures, with corresponding 95% confidence limits 
(CLs), were tested to determine whether the change was significantly different from 0, and 
results were considered statistically significant with a two-sided P value <0.05. The Figures 
show observed rates (symbols) and modeled trends (lines).
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RESULTS
CVD-Specific Hospitalization Rates by Diabetes Status
From 1998 to 2014, in both the population with and the population without diabetes, trends 
in age-adjusted hospitalization rates declined significantly for ACS, heart failure, and 
hemorrhagic and ischemic stroke (Table 1). However, throughout the period, rates for 
cardiac dysrhythmia hospitalization declined significantly only in the population with 
diabetes (AAPC −0.7% per year [95% CL −1.1, −0.2], P = 0.004) (Table 1).
Although throughout the period, with the exception of cardiac dysrhythmia rates in the 
population without diabetes, hospitalization rates for these CVD conditions declined 
significantly in both populations, in several instances the trend in the latter part of the period 
was different from the overall trend (Table 1). In the population with diabetes, rates leveled 
off for ACS (from 2009 to 2014) and for heart failure (from 2010 to 2014). Rates for 
ischemic stroke increased significantly (APC 3.1% per year [95% CL 1.6, 4.7], P = 0.001) in 
the population with diabetes (from 2009 to 2014) and leveled off in the population without 
diabetes (from 2006 to 2014). On the other hand, in the population without diabetes, 
although rates for cardiac dysrhythmia showed no significant change from 1998 to 2014, 
rates from 2011 to 2014 declined significantly (APC −7.2% per year [−10.3, −4.0], P = 
0.002) (Table 1).
From 1998 to 2014, the AAPCs in hospitalization rates were similar between the population 
with diabetes and the population without diabetes: for ACS, −4.6% per year (95% CL −5.3, 
−3.8) vs. −4.4% (−5.4, −3.4), respectively; for cardiac dysrhythmia, −0.7% per year (−1.1, 
−0.2) vs. −1.2% (−3.1, 0.8); for heart failure −3.6% per year (−4.6, −2.7) vs. −2.6% (−3.2, 
−2.0); for hemorrhagic stroke, −1.1% per year (−1.4, −0.7) vs. −1.5% (−1.8, −1.1); and for 
ischemic stroke, −2.9% per year (−3.9, −1.8) vs. −2.3% (−2.7, −1.9). However, despite these 
similar average rates of decline in both populations, compared with 1998, hospitalization 
rates in 2014 for these CVD conditions continued to be approximately two to four times 
higher in the population with diabetes than in the population without diabetes, with the 
largest relative difference (4.1 times) in heart failure rates.
CVD-Specific Hospitalizations in the Population With Diabetes
By Age—In 2014, in the population with diabetes, hospitalization rates for all CVD 
conditions studied were higher in the older population than in the younger population (Table 
2). The greater differences between those older and those younger were in rates for cardiac 
dysrhythmia (6.6 times) and for heart failure (6.0 times).
From 1998 to 2014, among those aged ≥55 years, trends in hospitalization rates declined 
significantly for all CVD conditions (Table 2). However, among those aged 35–54 years, 
overall trends declined only for ACS (AAPC −3.2% per year [95% CL −4.3, −2.0], P < 
0.001); remained unchanged for heart failure, hemorrhagic stroke, and ischemic stroke; and 
increased for cardiac dysrhythmia (AAPC 0.8% per year [0.1, 1.5], P = 0.03). Although in 
all age-groups the rates for ACS declined throughout the period, in the last 4–5 years of the 
study period the rates in all age-groups leveled off (Table 2). For ischemic stroke, rates 
increased in the last 4–5 years of the study period among those aged 35–74 years (APC 
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6.2% per year [2.6, 10.0], P = 0.003, for those aged 35–54 years and APC 2.6% [1.0, 4.3], P 
= 0.005, for those aged 55–74 years) and leveled off beginning in 2006 among those aged 
≥75 years.
By sex—In 2014, in the population with diabetes, hospitalization rates for ACS, cardiac 
dysrhythmia, heart failure, and hemorrhagic stroke (but not for ischemic stroke) were higher 
in men than in women (Table 2). From 1998 to 2014, hospitalization rates for ACS, heart 
failure, and hemorrhagic and ischemic stroke declined significantly in both men and women 
and rates in cardiac dysrhythmia remained unchanged in both men and women (Table 2; Fig. 
1). However, similar to what was seen with the age-specific hospitalization rates, the patterns 
of decline within the period differed between men and women.
Although throughout the period hospitalization rates for ACS and for heart failure declined 
in both men and women, the rates for ACS leveled off in both men and women in the last 4–
5 years of the study period and the rates for heart failure leveled off in men beginning in 
2007 (Table 2; Fig. 1). For cardiac dysrhythmia, even though the rates during the study 
period remained unchanged in both men and women, rates in women declined significantly 
from 2011 to 2014 (APC −5.6% per year [95% CL −9.9, −1.1], P = 0.02). For ischemic 
stroke, although rates throughout the period declined in both men and women, rates in the 
latter part of the period increased in both men (APC 4.2% per year [1.8, 6.6], P = 0.003) and 
women (APC 1.5% [0.1, 2.9], P = 0.04).
By Race/Ethnicity—In 2014, in the population with diabetes, in contrast with what was 
seen in rates by age and sex, racial/ethnic differences in hospitalization rates varied by CVD 
condition (Table 2). Compared with the other race/ethnicity groups, non-Hispanic whites 
had higher hospitalization rates for ACS (10.0 per 1,000 [95% CL 9.2, 10.8] vs. 7.9 [6.8, 
8.9] for non-Hispanic blacks and 6.3 [5.3, 7.3] for Hispanics) and for cardiac dysrhythmia 
(7.3 per 1,000 [6.7, 7.8] vs. 6.1 [5.3, 6.8] for non-Hispanic blacks and 3.9 [3.2, 4.6] for 
Hispanics). On the other hand, non-Hispanic blacks had higher hospitalization rates for heart 
failure (22.1 per 1,000 [19.3, 24.9] vs. 12.9 [12.0, 13.9] for non-Hispanic whites and 9.7 
[8.0, 11.3] for Hispanics), hemorrhagic stroke (1.4 per 1,000 [1.2, 1.6] vs. 0.9 [0.8, 1.0] for 
non-Hispanic whites and 1.0 [0.8, 1.2] for Hispanics), and ischemic stroke (9.0 per 1,000 
[7.9, 10.1] vs. 6.1 [5.6, 6.5] for non-Hispanic whites and 4.5 [3.8, 5.2] for Hispanics). In 
contrast, compared with the other groups, Hispanics had lower hospitalization rates for 
cardiac dysrhythmia, heart failure, and ischemic stroke.
From 1998 to 2014, hospitalization rates for ACS declined significantly for non-Hispanic 
whites and Hispanics (AAPC −3.2% per year [95% CL −4.9, −1.6] and −4.0% [−5.3, −2.6], 
respectively, both P < 0.001) and showed no significant change for non-Hispanic blacks 
(Table 2; Fig. 2). For heart failure, rates decreased significantly for non-Hispanic whites 
only (AAPC −2.8% per year [−3.5, −2.1], P < 0.001) and remained unchanged for the other 
two groups. However, for cardiac dysrhythmia, rates throughout the period increased 
significantly for non-Hispanic blacks (AAPC 2.2% per year [0.9, 3.5], P = 0.002) and 
remained level for the other two groups. For hemorrhagic and ischemic stroke, rates during 
the study period showed no significant change in all three race/ethnicity groups. However, 
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similar to the trends in the other demographic groups, patterns of decline within the study 
period differed by race/ethnicity group.
Although throughout the period hospitalization rates for ACS and for heart failure declined 
significantly in non-Hispanic whites, in this group the rates of ACS increased (APC 4.5% 
per year [95% CL 2.1, 6.9], P = 0.002) from 2009 to 2014 and the rates of heart failure 
leveled off beginning in 2007 (Table 2; Fig. 2). In contrast, among Hispanics, the rates for 
heart failure declined from 2003 to 2014 (APC −6.7% per year [−8.6, −4.7], P < 0.001). 
Even though throughout the period rates for hemorrhagic and ischemic stroke showed no 
consistent change for all three race/ethnicity groups, rates for hemorrhagic stroke in the 
latter part of the period increased for non-Hispanic whites (APC 2.6% per year [2.1, 3.2], P 
< 0.001), and rates for ischemic stroke also increased for non-Hispanic whites (APC 6.5% 
per year [4.8, 8.2], P < 0.001) and for non-Hispanic blacks (APC 4.6% per year [1.0, 8.3], P 
= 0.02).On the other hand, from 2003 to 2014, hospitalization rates for hemorrhagic stroke 
among Hispanics declined (APC −3.0% per year [−4.9, −1.0], P = 0.006).
CONCLUSIONS
Heart disease and stroke are leading causes of death in the U.S. (16). In this analysis of 
nationally representative data, we documented from 1998 to 2014 significant declines in 
hospitalization rates for ACS, heart failure, and hemorrhagic and ischemic stroke, in both the 
population with diabetes and the population without diabetes, and a significant decline in 
cardiac dysrhythmia rates in the population with diabetes only. The average rate of decline 
for the entire period was similar in both populations. However, compared with the 
population without diabetes, and with the exception of cardiac dysrhythmia and hemorrhagic 
stroke, rate differences between 1998 and 2014 were greater in the population with diabetes. 
Thus, despite these encouraging trends, hospitalization rates in 2014 for these CVD 
conditions remained 2–4 times as high in the population with diabetes than in the population 
without diabetes, with the largest difference in heart failure rates.
Other population-based studies—three international and one of a U.S. state—have reported 
declining trends in hospitalization rates in the population with diabetes for AMI (which is a 
condition within ACS) (17–19), heart disease (including ischemic heart disease, cardiac 
dysrhythmia, and heart failure) (20), and stroke (17,19,20). Two studies compared trends in 
AMI and stroke hospitalization rates by diabetes status (17,18). One study of the population 
of Ontario, Canada, found that AMI and stroke rates declined more in the population with 
diabetes than in the population without diabetes between 1992 and 2000 (17). The second 
study, in England, found no difference in AMI and stroke trends by diabetes status between 
2004 and 2010, consistent with our findings in trends of ACS and hemorrhagic and ischemic 
stroke (18). In both of these international studies (17,18), similar to our findings, 
hospitalization rates at the end of the study period were still greater in the population with 
diabetes than in the population without diabetes. Our findings of decreasing trends in ACS, 
cardiac dysrhythmia, heart failure, and both hemorrhagic and ischemic stroke hospitalization 
rates in the population with diabetes in the U.S. are also consistent with a study that found 
remarkable improvements in CVD death rates from 1997 to 2006 among U.S. adults with 
diabetes (40% decrease) (7).
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Declining trends in AMI and stroke hospitalization and mortality rates in the U.S. general 
population (i.e., populations with diabetes and without diabetes combined) are well-
documented (21–25). Our findings showing that hospitalization rates for heart failure 
declined significantly from1998 to 2014 in both the population with diabetes and the 
population without diabetes are in contrast with a study indicating that overall 
hospitalization rates from 2000 to 2010 showed no significant change for congestive heart 
failure (26) but are consistent with another study showing that overall death rates for heart 
failure decreased from2000 to 2012 (27). Furthermore, a study based on NIS data (28) 
reported an increase from 2000 to 2010 in the overall hospitalization rate for atrial 
fibrillation—the most common arrhythmia leading to hospitalization—in seeming contrast 
to our findings showing that hospitalization rates for cardiac dysrhythmia declined from 
1998 to 2014 in the population with diabetes and showed no consistent trend in the 
population without diabetes from 1998 to 2011. However, when we looked at atrial 
fibrillation alone (data not shown), we found that rates increased throughout the study period 
in the population with diabetes and from 2004 to 2011 in the population without diabetes. 
This suggests that dysrhythmia hospitalizations for causes other than atrial fibrillation 
differed from trends in atrial fibrillation.
Declines in CVD hospitalization rates occurred despite the increased use of more sensitive 
laboratory tests (e.g., biomarkers) that have improved detection of heart attacks and strokes 
(29). Improvements in CVD morbidity and mortality might be due to several factors, 
including prevention or improved control of CVD risk factors (e.g., smoking, cholesterol, 
blood pressure); new or more aggressive treatments for CVD and its risk factors; improved 
detection and management of precursor conditions, such as subclinical atherosclerosis; 
better management of underlying diseases (including diabetes); and access to regular care, or 
other factors (11,12,29–32). We cannot determine from our surveillance data the reasons for 
the greater improvements (i.e., the larger rate differences) in ACS, heart failure, and 
ischemic stroke rates among those with diabetes. However, one potential explanation may be 
that adults with diabetes differentially benefited from new treatments and improvements to 
CVD risk factors either because they have higher levels of CVD risk factors than those 
without diabetes and thus have greater opportunity for improvement or because they were 
treated more aggressively owing to their high risk status. For example, although statin use 
has increased in the U.S. population (29,32–35), one study found the use of statins or other 
cholesterol-lowering medication to be higher and to have increased faster among people with 
diabetes than among those without diabetes (36), and population-based studies have found 
greater relative improvements in cholesterol and lipid levels among people with diabetes 
than in those without (32,37). In addition, between 1999 and 2010, the proportion of adults 
with diabetes achieving glycemic control and those achieving blood pressure control 
increased significantly (12).
Despite the encouraging trends in most of the CVD conditions studied, trends in several 
subgroups of the population with diabetes are of concern. In the latter years, after an initial 
period of decline, hospitalization rates leveled off for ACS in all age-groups, in men, in 
women, and in non-Hispanic blacks; for heart failure in men and in non-Hispanic whites; 
and for ischemic stroke in people aged ≥75 years and in Hispanics. In addition, throughout 
the period, hospitalization rates remained level for cardiac dysrhythmia in men, non-
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Hispanic whites, and Hispanics; for heart failure in those aged 35–54 years and non-
Hispanic blacks; and for hemorrhagic stroke in those aged 35–54 years and non-Hispanic 
blacks. Reasons for why these rates are no longer declining in some population subgroups 
cannot be determined from our surveillance data; however, they may reflect demographic 
differences in treatment and uptake of treatments, a differential impact of preventive 
treatment or risk factor control, or other factors (38). Even more concerning, several trends 
in the population with diabetes showed a significant increase. In particular, in the latter part 
of the study period, ischemic stroke hospitalization rates increased in most of the 
subpopulations studied: in those aged 35–74 years, men, women, non-Hispanic whites, and 
non-Hispanic blacks. Increases were also seen for ACS in non-Hispanic whites (2009–
2014), for cardiac dysrhythmia in people aged 35–54 years and in non-Hispanic blacks 
(1998–2014), and for hemorrhagic stroke in non-Hispanic whites (2002–2014). Reasons for 
these recent increases are unclear. Shifting patterns of case finding as a result of improved 
access to care may be underway, identifying a pool of higher-risk patients and changing the 
epidemiologic characteristics of the population with diabetes. Also, declines in diabetes 
incidence (39) and decreases in mortality (7,8,10) may have resulted in a population with 
diabetes that is older and has longer duration of disease and is therefore more susceptible to 
the development of diabetes complications. More years of data and continued surveillance of 
CVD hospitalizations in the population with diabetes will be needed to confirm these trends.
Our study has a major strength in that we used nationally representative surveys to examine 
trends in hospitalization of selected CVD conditions among people with and without 
diagnosed diabetes. However, it also has several limitations. First, although the CVD 
conditions studied are likely to result in hospital admissions, the findings need to be 
interpreted with caution given that health care practices have changed during the study 
period (29,31). Second, because NIS samples hospital discharges and not individual persons, 
NIS hospital discharge rates may not necessarily reflect rates per person; that is, persons 
who are hospitalized more than once in the same calendar year may be counted more than 
once. Although repeat hospitalizations overestimate the hospitalization rates, ratios of rates 
in the population with diabetes versus the population without diabetes with and without 
repeat hospitalizations may not be significantly affected (40). Third, we cannot distinguish 
persons with prior known CVD from those without and thus cannot determine whether CVD 
incidence rates are actually declining. Recent managed-care data show that reductions in 
death rates may be driven by people with prior history of CVD (41). Fourth, estimates of the 
population with diagnosed diabetes were based on self-report and did not include persons 
with undiagnosed diabetes or prediabetes or persons residing in nursing homes (15). Finally, 
new diagnostic criteria for diabetes in 1997 that lowered the threshold of the fasting glucose 
value from 140 to 126 mg/dL (9) may have resulted in a greater number of individuals with 
milder disease, detected earlier in the disease process, and contributed to the overall decline 
in CVD hospitalization rates. However, throughout the period, hospitalization rates for ACS, 
heart failure, and hemorrhagic and ischemic stroke declined significantly in both the 
population with diabetes and the population without diabetes.
Despite our encouraging findings, CVD remains a major preventable cause of morbidity and 
the most common cause of death for adults with diabetes (1,2). Furthermore, important 
disparities continue to persist, including greater CVD hospitalization rates for adults with 
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diabetes than in adults without diabetes, among older people with diabetes compared with 
those younger, and among men with diabetes compared with women. Also, compared with 
non-Hispanic whites, non-Hispanic blacks with diabetes had higher hospitalization rates for 
heart failure and for stroke (both ischemic and hemorrhagic), as well as potentially 
geographical disparities that have previously been reported (24) but that we were unable to 
examine. In addition, our outcomes do not capture the full range of CVD morbidity, as data 
from the U.S. Renal Data System or from other sources suggest that very large differences 
between subgroups remain in other CVD outcomes, including cardiomyopathy, sudden 
cardiac arrest, and CVD associated with kidney failure (2,19,29,42). Although diabetes care 
in the U.S. has improved, broad opportunities remain to reduce rates of smoking, 
hyperglycemia, hyperlipidemia, and uncontrolled hypertension (12), particularly among 
people in younger age-groups and minority populations (38). Continued and additional 
efforts, such as promoting lifestyle changes that include increased physical activity and 
healthier eating (43), might be considered to improve CVD risk factor control, sustain and 
improve the declining hospitalization trends in CVD conditions in both the population with 
diabetes and the population without diabetes, and further reduce the excess risk for heart 
failure and stroke among non-Hispanic blacks with diabetes.
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Figure 1. 
Age-adjusted hospitalization rates for selected CVD conditions among people aged ≥35 
years with diagnosed diabetes, by sex (U.S., 1998–2014). Per 1,000 population with diabetes 
and age-adjusted based on the 2000 U.S. standard population. Symbols represent observed 
hospitalization rates, and lines represent modeled trends using Joinpoint regression. ■, heart 
failure; □, ACS; △, ischemic stroke; ●, cardiac dysrhythmia; ◆, hemorrhagic stroke.
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Figure 2. 
Age-adjusted hospitalization rates for selected CVD conditions among people aged ≥35 
years with diagnosed diabetes, by race/ethnicity (U.S., 1998–2014). Per 1,000 population 
with diabetes and age-adjusted based on the 2000 U.S. standard population. Symbols 
represent observed rates, and lines represent modeled trends. ■, heart failure; □, ACS; △, 
ischemic stroke; ●, cardiac dysrhythmia; ◆, hemorrhagic stroke.
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